Abstract
Serdexmethylphenidate (SDX) chloride is a novel prodrug of d-methylphenidate (d-MPH) that has been incorporated into 2 investigational products (KP415 and KP484) for the treatment of ADHD. SDX was rationally designed to provide extended-duration d-MPH exposure while being pharmacologically inactive until converted metabolically in the lower intestines. The objective of the current 3 studies was to evaluate the human abuse potential of SDX when administered by routes commonly reported by stimulant abusers (oral, intranasal [IN], intravenous [IV]).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
